OncoSil Medical Limited chart

Last update: 2021-02-19
Key statistics and financials
Revenue per share 0.00
Dividend & YieldN/A$ (N/A)
Beta 0.36
Market capitalization 61.46M
Operating cash flow -11.15M
ESG Scores unknown

Company description

OncoSil Medical Limited, a medical device company, focuses on the development and commercialization of localized radiation therapy for the treatment of pancreatic and bile duct cancer in Australia. Its lead product is OncoSil, a brachytherapy device indicated for the treatment of patients with locally advanced unresectable pancreatic cancer, in combination with gemcitabine-based chemotherapy. The company was formerly known as NeuroDiscovery Limited and changed its name to OncoSil Medical Limited in May 2013. OncoSil Medical Limited was incorporated in 2005 and is headquartered in North Sydney, Australia.

Sector: Healthcare - Industry: Medical Devices

Financial data

Financial Statements

Cashflow Statement 2018-06-30 2019-06-30 2020-06-30 2021-06-30
Change To Liabilities 75.34k -816.44k 1.01M -49.32k
Total Cashflows From Investing Activities -10.7k -14.83k -20.72k -54k
Net Borrowings -94.53k -94.53k -94.53k -148.75k
Total Cash From Financing Activities 15.61M 17.79M 17.79M 111.25k
Change To Operating Activities -919.14k 756.24k 1.04M 1.54M
Issuance Of Stock 16.71M 19.04M 19.04M
Net Income -8.54M -8.57M -4.26M -10.43M
Change In Cash 7.2M -7.52M 13.31M -8.76M
Effect Of Exchange Rate
Total Cash From Operating Activities -8.4M -7.5M -4.46M -8.82M
Depreciation 39.91k 38.62k 149.29k 184.78k
Change To Account Receivables -28.69k -28.69k -28.69k -28.69k
Other Cashflows From Financing Activities -1.1M -1.16M -1.16M 260k
Change To Netincome 946.09k 1.09M -2.39M -31.37k
Capital Expenditures -10.7k -14.83k -20.72k -54k

Income Statement 2018-06-30 2019-06-30 2020-06-30 2021-06-30
Research Development 5.83M 5.58M 3.73M 2.89M
Income Before Tax -8.54M -8.57M -4.26M -10.43M
Net Income -8.54M -8.57M -4.26M -10.43M
Selling General Administrative 7.26M 6.84M 3.47M 7.99M
Gross Profit 4.45M 3.63M 2.76M 337.3k
Ebit -8.64M -8.79M -4.43M -10.54M
Operating Income -8.64M -8.79M -4.43M -10.54M
Interest Expense -25.43k -25.43k -25.43k -15.75k
Income Tax Expense
Total Revenue 4.45M 3.63M 2.76M 1.3M
Cost Of Revenue 961.02k
Total Other Income ExpenseNet 101.84k 218.96k 169.54k 108.37k
Net Income From Continuing Ops -8.54M -8.57M -4.26M -10.43M
Net Income Applicable To Common Shares -8.54M -8.57M -4.26M -10.43M

Balance Sheet Statement 2018-06-30 2019-06-30 2020-06-30 2021-06-30
Total Liabilities 1.73M 993.21k 2.16M 2.45M
Total Stockholder Equity 18.15M 10.68M 21.9M 11.7M
Other Current Liabilities 38.8k 304.84k 208.4k 232.24k
Total Assets 19.88M 11.67M 24.06M 14.15M
Common Stock 52.26M 52.26M 70.14M 70.4M
Other Current Assets 84.97k 69.21k 69.21k 90.53k
Retained Earnings -39.04M -47.6M -51.86M -62.3M
Treasury Stock 4.93M 6.02M 3.63M 3.6M
Cash 15.21M 7.69M 21M 12.24M
Total Current Liabilities 1.73M 993.21k 2.16M 2.13M
Other Stockholder Equity 4.93M 6.02M 3.63M 3.6M
Property, Plant, and Equipment 86.25k 62.47k 138.37k 530.78k
Total Current Assets 19.8M 11.61M 23.92M 13.62M
Net Tangible Assets 18.15M 10.68M 21.9M 11.7M
Net Receivables 4.48M 3.82M 2.81M 1.18M
Accounts Payable 857.11k 363.99k 1.36M 1.23M


Insider Transactions

Here are the insider transactions of stock shares related to OncoSil Medical Limited:

Filer Name Transaction Text Ownership Date Filer Relation Shares
Buttula (Otto Leslie Steven)Other at price 0.04 per share.D2022-06-10Director (Non-Executive)4.62M
Cross (Martin George)Other at price 0.04 per share.D2022-06-10Director (Non-Executive)461.54k
Lange (Nigel)Other at price 0.04 per share.D2022-06-10Chief Executive Officer500k
Bassett (Michael)D2021-10-19Former1.12M
Roberts (Christopher Graham)D2021-10-19Former4.64M
Cross (Martin George)Purchase at price 0.04 per share.D2021-08-24Director (Non-Executive)95k
Pechmann (Karl)D2021-06-30Chief Financial Officer684.93k
Roberts (Christopher Graham)D2021-05-10Non Executive Chairman10M
Aston (Roger)D2020-12-18Executive Chairman500k
Kenny (Daniel)D2020-12-18Chief Executive Officer23.08M
Kenny (Daniel)D2020-11-05Chief Executive Officer2.78M
Roberts (Christopher Graham)Purchase at price 0.10 per share.D2020-10-27Non Executive Chairman3M
Cross (Martin George)Purchase at price 0.10 per share.D2020-10-23Director (Non-Executive)177.73k
Aston (Roger)D2020-06-30Executive Chairman500k
Cross (Martin George)I2020-06-30Director (Non-Executive)
Kenny (Daniel)D2020-06-30Chief Executive Officer2.7M
Milicevic (Tom)D2020-06-30Former5.75M
Aston (Roger)Other at price 0.06 per share.D2020-05-28Executive Chairman1.14M
Bassett (Michael)Other at price 0.06 per share.D2020-05-28Director (Non-Executive)93k
Cross (Martin George)Other at price 0.06 per share.D2020-05-28Director (Non-Executive)227.27k
Kenny (Daniel)Other at price 0.06 per share.D2020-05-28Chief Executive Officer11.11k
Roberts (Christopher Graham)Other at price 0.06 per share.D2020-05-28Non Executive Chairman1.06M
Cross (Martin George)Purchase at price 0.08 per share.D2020-03-09Director (Non-Executive)485k
Cross (Martin George)Purchase at price 0.05 per share.D2019-09-05Director (Non-Executive)135k
Roberts (Christopher Graham)Purchase at price 0.04 per share.D2019-08-26Non Executive Chairman500k
Milicevic (Tom)D2019-06-30Chief Financial Officer650k
Cross (Martin George)Purchase at price 0.06 per share.D2019-05-07Director (Independent)230k
Bassett (Michael)Purchase at price 0.04 per share.D2019-05-02Director (Non-Executive)800k
Cross (Martin George)Purchase at price 0.04 per share.D2019-04-01Director (Independent)358.33k
Kenny (Daniel)D2018-10-31Chief Executive Officer3M
Milicevic (Tom)D2018-06-30Chief Financial Officer41.67k
Cross (Martin George)Other at price 0.09 per share.D2018-05-17Director (Independent)166.67k
Roberts (Christopher Graham)Other at price 0.09 per share.D2018-05-17Director (Non-Executive)1M
Aston (Roger)D2018-05-05Executive Chairman500k
Cross (Martin George)Other at price 0.09 per share.D2018-04-20Director (Independent)125k
Kenny (Daniel)Other at price 0.09 per share.D2018-04-20Chief Executive Officer41.67k
Roberts (Christopher Graham)Other at price 0.09 per share.D2018-04-20Director (Non-Executive)125k
Aston (Roger)D2018-01-30Executive Chairman1M
Kenny (Daniel)D2018-01-30Chief Executive Officer6M
Milicevic (Tom)D2017-09-11Chief Financial Officer55k
Kenny (Daniel)D2016-09-05Chief Executive Officer14M
Rogers (Martin Frederick)D2016-06-30Director (Non-Executive)20.15k
Gozlan (Lawrence)D2015-05-04Former7.5M
Aston (Roger)Other at price 0.11 per share.D2014-11-28Executive Chairman2M
Rogers (Martin Frederick)Purchase at price 0.12 per share.D2014-03-17Chairman of the Board385k
Rogers (Martin Frederick)Purchase at price 0.11 per share.D2013-12-02Chairman of the Board662k
Rogers (Martin Frederick)Other at price 0.09 per share.D2013-10-30Chairman of the Board5M
Frazer (Neil)Other at price 0.09 per share.D2013-10-30Chief Executive Officer20M
Aston (Roger)Other at price 0.12 per share.D2013-10-25Executive Chairman115.38k
Frazer (Neil)D2013-10-25Chief Executive Officer115.48k
Rogers (Martin Frederick)Other at price 0.12 per share.D2013-10-25Chairman of the Board115.38k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to OncoSil Medical Limited. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on OncoSil Medical Limited

Here is the result of two systematic investment strategies applied to OncoSil Medical Limited. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on OncoSil Medical Limited

The following chart shows the equity curve of the two systematic investment strategies applied to OncoSil Medical Limited:

OncoSil Medical Limited automated entries

The systematic investment strategy that buys the first day of the month would give a performance of -10.24% on the backtest period.

Performance at glance

Performance

-10.24 %

Latent gain

-255.92 $

Invested capital

2500.14 $

Annualized return

-2.47 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on OncoSil Medical Limited

This is the result of two momentum investment strategies applied to OncoSil Medical Limited. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on OncoSil Medical Limited

The following chart shows all the entries opened by the momentum investment system on OncoSil Medical Limited:

OncoSil Medical Limited momentum entries
  • The first momentum investment strategy would give -5.25% of return on OncoSil Medical Limited. That represents -327.93$ of latent gain with 6250.11$ of employed capital.
  • The second momentum investment strategy would give 4.45% of return on OncoSil Medical Limited. That represents 111.34$ of latent gain with 2500.17$ of employed capital.
Performance at glance (1Q Momentum)

Performance

-5.25 %

Latent gain

-327.93 $

Invested capital

6250.11 $

Annualized return

-7.81 %
Performance at glance (2Q Momentum)

Performance

4.45 %

Latent gain

111.34 $

Invested capital

2500.17 $

Annualized return

1.22 %

Momentum equity curve on OncoSil Medical Limited

The following chart shows the equity curve of the two momentum strategies applied to OncoSil Medical Limited:

OncoSil Medical Limited momentum equity

Note: the dividends potentially given by OncoSil Medical Limited are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on OncoSil Medical Limited

The following chart shows the employed capital evolution of the two momentum strategies on OncoSil Medical Limited since the beginning:

OncoSil Medical Limited

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on OncoSil Medical Limited

Buy the dip entry openings on OncoSil Medical Limited

OncoSil Medical Limited

The performance achieved by the robo-advisor on OncoSil Medical Limited is -16.71%. That represents -167.16$ of latent gain with 1000.08$ of employed capital. The following chart shows OncoSil Medical Limited stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of OncoSil Medical Limited, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

-16.71 %

Latent gain

-167.16 $

Invested capital

1000.08 $

Annualized return

-7.81 %

Equity curve of the strategy applied to OncoSil Medical Limited

The following chart shows the result of the investment strategy applied to OncoSil Medical Limited:

OncoSil Medical Limited

Note: the dividends potentially given by OncoSil Medical Limited are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on OncoSil Medical Limited

The following chart shows the employed capital evolution since the beginning of the investment strategy on OncoSil Medical Limited:

OncoSil Medical Limited

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on OncoSil Medical Limited

In this section, I will compare the three previous investment strategies applied to OncoSil Medical Limited.

Equity curve comparison on OncoSil Medical Limited

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

OncoSil Medical Limited investment strategy comparison

Employed capital comparison on OncoSil Medical Limited

OncoSil Medical Limited investment comparison

Performance comparison on OncoSil Medical Limited

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment -10.24% -255.92$ 2500.14$ -2.47%
Momentum 1 quarter -5.25% -327.93$ 6250.11$ -1.35%
Momentum 2 quarters 4.45% 111.34$ 2500.17$ 1.22%
Non-directional -16.71% -167.16$ 1000.08$ -7.81%
Annualized return comparison

Automatic investment

-2.47 %

Momentum 1Q

1.22 %

Momentum 2Q

1.22 %

Non-directional

-7.81 %

Correlated stocks

Here are the most positively and negatively correlated stocks with OncoSil Medical Limited:

Positive correlations

Most correlated stocks this year


Most correlated stocks last 3 months

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

Note: The algorithm computes the probability of correlation between OncoSil Medical Limited and the other stocks. There may be false positives or some missing correlated stocks. If the price of OncoSil Medical Limited does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name OncoSil Medical Limited
Country Australia
City North Sydney
Address 15 Blue Street
Phone 61 2 9223 3344
Website www.oncosil.com.au
FullTime employees
Industry Medical Devices
Sector Healthcare
Exchange XASX
Ticker OSL.XASX
Market www2.asx.com.au

OncoSil Medical Limited ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown